Imexhs Ltd · ASX:IME
Imexhs — Investor Presentation (October 2020)
25 slides from Imexhs's investor presentation, October 2020
Slide 1: Capital Raising
Built by physicians for physicians Capital Raising October 2020 1
Slide 2: Executive Summary
Executive Summary Business • Solid 3Q FY20 result with YTD revenue of $6.7m up 21% on pcp1, annualised recurring Update revenue (ARR) of $9.0m up 11%2 • Significant progress made in new markets and good traction for Aquila in the Cloud Growth • Significant organic growth opportunity as IMEXHS expand
Slide 3: Agenda
Agenda 1. About IMEXHS 2. Business Update 3. Capital Raising 3
Slide 4: About IMEXHS
ime xHs About mes
Slide 5: Leading innovator in medical imaging
Leading innovator in medical imaging • Next Generation multi-modality • Scalable, modular HIRUKOTM cloud-based medical imaging software platform provides solutions for all with over 250 sites globally complexity levels • Subscription model with >90% of • Aquila in the Cloud standardised revenue recu
Slide 6: Expanding global footprint
Expanding global footprint Spain USA 15 countries Mexico >250 sites Honduras El Salvador Nicaragua Australia Costa Rica Colombia >2,000 radiologists Panama Ecuador 23 distributors Peru Brazil 1/3 of team in Bolivia Paraguay software development Chile Uruguay IMEXHS currently operating Argentina Agre
Slide 7: Significant global opportunity
Significant global opportunity • Global market is valued at US$2.7bn RIS/PACS • Estimated Put 3to growpoints bullet at 7.4% CAGR 2018 US$2.7bn • and text here Projected global RIS/PACS market of $5.0bn in 2027 2027 US$5.0bn • This only captures Radiology Imaging Systems • Further upside from other m
Slide 8: Our competitive advantage
Our competitive advantage ACCESSIBILITY CAPABILITY FLEXIBILITY AFFORDABILITY • Fully web & cloud-based • Single platform and archiving • Multi-modality • Lower cost base than • Teleradiology accessed from system • Scalable modular solutions for competitors any device or browser • Multi-tenant archit
Slide 9: HIRUKO medical imaging platform
HIRUKOTM medical imaging platform Advanced Stella Vital Alma Braviz Post-processing AI 3D ADv 3D Basic Enterprise Aquila Alula Anteros Imaging Radiology Pathology Cardiology Core Platform HIRUKOTM Universal Portals Multi-Tenancy PACS/VNA Viewer Nuance 360 IMEXHS LTD | CAPITAL RAISING (ASX:IME) *Comp
Slide 10: End-to-end modular imaging solution
End-to-end modular imaging solution Scan scheduled via our platform Uploaded to our platform Archived on our cloud-based platform Manages Billing } 1)Business Intelligence 2)Statistical Data 3. 4. 5. 1. 2. Radiologist Referring Physician Billing Physician Patient has interprets scanned reviews image
Slide 11: Advanced streaming technology
Advanced streaming technology Pixel Info Bandwidth Optimisation Other Info Any web Medical Image VNA Server Rendering Server enabled device IMEXHS LTD | CAPITAL RAISING (ASX:IME) 11
Slide 12: Developing AI capabilities
Developing AI capabilities • Access to over 700m images for AI development IMAGES • Provide interpretation services to enhance AI image library 726m • Create test bed for the development and training of 488m AI tools • Developed Stella AI which identifies normal and 231m pathological radiological pa
Slide 13: Industry trends: Healthcare IT sector
INDUSTRY TRENDS: Healthcare IT sector Increasing use of Large, rapidly radiological Chronic global Shift from client growing but highly Increased proportion techniques in wider radiologist shortage server architecture to fragmented global of the value chain clinical applications, driving demand for
Slide 14: Business Update
ime xHs Business Unde
Slide 15: 3Q20 Financial Highlights
3Q20 Financial Highlights YTD Sales Revenue of ARR3 of Recurring revenue of $6.7m $9.0m $1.9m Up 21% on pcp1, up 34% on Up 11% on pcp, 30% on a Down 16% on pcp, down constant currency2 basis constant currency basis 1% on constant currency basis Aquila in the Cloud Closing cash of Recurring revenue 1
Slide 16: 1H20 Financial Highlights
1H20 Financial Highlights Sales Revenue of ARR of EBITDA of $4.5m $8.8m ($1.3m) Up 68% on pcp1, new Up 5% on pcp, 20% on a Improvement of $0.5m, contract wins & renewals constant currency basis $0.1m on like for like basis3 Recurring revenue of Closing cash of Underlying EBITDA4 of $4.25m $6.3m ($0.
Slide 17: FY20 Outlook
FY20 Outlook USA – Increase sales presence Trading in second half in line with leveraging the new sales office company expectations established in Florida Brazil – Promotion activity to Some impact from second waves of capitalise on ANVISA certification COVID-19 in key markets Australia – Commence s
Slide 18: Capital Raising
ime xHs Capital cling
Slide 19: Details of the Offer
Details of the Offer Offer of New Shares • The Company seeks to raise up to A$8.3 million by way of a Placement of approximately 276 million new fully paid ordinary shares in the Company (“New Shares”) at A$0.03 per share • The Offer is not underwritten • The Placement will take place under the Comp
Slide 20: Use of Proceeds
Use of Proceeds 1. Accelerate International Expansion – Invest in Sales & Marketing • USA - World’s largest RIS & PACS market, Total Addressable Market (TAM) US$1.2 billion • Brazil - Latin America’s largest market • Australia • Digital Sales – Ingram Micro Marketplace, Cloud Blue etc. 2. Software D
Slide 21: Appendix
ime xHs sapere
Slide 22: Our board of directors
Our board of directors Doug Flynn Carlos Palacio Dr Doug Lingard Damian Banks Dr German Arango Non-Executive Non-Executive Non-Executive Non-Executive CEO and Managing Chairman Director Director Director Director IMEXHS LTD | CAPITAL RAISING (ASX:IME) 22
Slide 23: Our executive team
Our executive team Dr German Arango Dr Jorge Marín Alejandro Alexander Sanz Reena Minhas Managing Director & Chief Medical Officer Varettoni Chief Technology Chief Financial Officer CEO Chief Sales Officer Officer & Company Secretary IMEXHS LTD | CAPITAL RAISING (ASX:IME) 23
Slide 24: Disclaimer
Disclaimer Summary Information actual calculation of these figures may differ from the figures set out in this presentation. This presentation has been prepared by IMEXHS Limited ACN 096 687 839 (“IMEXHS” or the “Company”). It is intended only for those persons to whom it is delivered personally by
Slide 25: Disclaimer
Disclaimer presentation, or any other written or oral information provided by or on behalf of the Company. in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Confidentiality This document and the information in thi